# A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer

> **NCT04982926** · PHASE1 · TERMINATED · sponsor: **Taiho Oncology, Inc.** · enrollment: 29 (actual)

## Conditions studied

- Solid Tumor
- Glioblastoma
- Non-small Cell Lung Cancer
- Breast Cancer

## Interventions

- **DRUG:** TAS2940
- **DRUG:** TAS2940

## Key facts

- **NCT ID:** NCT04982926
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-16
- **Primary completion:** 2025-02-26
- **Final completion:** 2025-03-24
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** After careful review of Taiho's ongoing portfolio and data obtained so far in the context of broader landscape of clinical development in NSCLC HER2mut, Sponsor has made a strategic decision to terminate this study and not based on safety concerns.
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04982926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04982926, "A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04982926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*